By Jim FreDerick
NEW YORK — For pharmaceutical manufacturers, wholesalers or retailers, the distinct chill over the past couple of years isn’t just some abstract news from the nation’s financial press; it’s the downdraft created by falling U.S. demand for brand-name prescription medicines.
Stymied by weak demand in a recessionary economy, intensifying generic competition, a relative dearth of research-and-development breakthroughs and an ongoing loss of patent protection for some of their biggest-selling pioneering medicines, branded pharmaceutical manufacturers have scrambled over the last three years to restore their once-enviable track record for product innovation and sales growth. And 2009 was no exception.
Reporting on industry trends for the 12-month period ended June 2009, IMS Health tracked a dismal performance record for the branded drug industry. While total retail prescription drug sales rose 4.2% to roughly $300 billion, the real action was almost all in the generic and specialty/biotech segment of the market. Sales of brand-name pharmaceuticals were up 2.7% for the period, thanks
Source: IMS Health, MIDAS, National Sales Perspectives, Rx-only, June 2009
Continued on page 6
0.3%
4.7%
0.9%
0.4%
ma T JUNe 2009
10.7%
35.0%
U.s. iNDUs Try
$291,804
100.0%
3.2%
11.5%
1. Lipid regulators
16,811
5. 8
2. Antipsychotics, other
14,222
4.9
3. 3
7.1%
3. Proton-pump inhibitors
13,891
4.8
4. Antidepressants
11,420
3. 9
16.7%
12.6%
5. Angiotensin II antagonists
7,946
2. 7
12. 9
6. Seizure disorders
7,773
2. 7
7,670
2. 6
9. 3
Chain
Independents
Mail service
Food stores
Clinics
Hospitals
Long-term care
Home health care
8. Erythropoietins
6,450
2. 2
5,938
2.0
13. 6
HMO Other
10. Analogs of human insulin
5,699
2.0
28. 8
TOP 10
$97,819
33.5%
0.4%
Source: IMS Health, National Sales Perspectives, June 2009
*In millions
Source: IMS Health, National Sales Perspectives, June 2009
References:
Archives